{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T16:23:01Z","timestamp":1774023781421,"version":"3.50.1"},"reference-count":133,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2024,4,24]],"date-time":"2024-04-24T00:00:00Z","timestamp":1713916800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,4,24]],"date-time":"2024-04-24T00:00:00Z","timestamp":1713916800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"DOI":"10.1007\/s12094-024-03491-8","type":"journal-article","created":{"date-parts":[[2024,4,24]],"date-time":"2024-04-24T18:01:48Z","timestamp":1713981708000},"page":"2431-2443","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Recent updates in the therapeutic uses of Pembrolizumab: a brief narrative review"],"prefix":"10.1007","volume":"26","author":[{"given":"V\u00edtor","family":"Silva","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6279-1421","authenticated-orcid":false,"given":"Cristiano","family":"Matos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,4,24]]},"reference":[{"key":"3491_CR1","first-page":"3","volume":"12","author":"S Jitender","year":"2017","unstructured":"Jitender S, Mahajan R, Rathore V, Choudhary R. Quality of life of cancer patients. J Exp Ther Oncol. 2017;12:3.","journal-title":"J Exp Ther Oncol"},{"issue":"3","key":"3491_CR2","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1001\/jamaoncol.2021.6987","volume":"8","author":"J Kocarnik","year":"2022","unstructured":"Kocarnik J, Compton K, Dean F, Fu W, Gaw B, Harvey J, et al. Cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life years for 29 cancer groups from 2010 to 2019. JAMA Oncol. 2022;8(3):420. https:\/\/doi.org\/10.1001\/jamaoncol.2021.6987.","journal-title":"JAMA Oncol"},{"key":"3491_CR3","doi-asserted-by":"publisher","unstructured":"Pucci C, Martinelli C, Ciofani G. Innovative approaches for cancer treatment: current perspectives and new challenges. ecancer. 2019;13:961. https:\/\/doi.org\/10.3332\/ecancer.2019.961.","DOI":"10.3332\/ecancer.2019.961"},{"issue":"1","key":"3491_CR4","doi-asserted-by":"publisher","first-page":"68","DOI":"10.3390\/ijerph14010068","volume":"14","author":"L Yu","year":"2017","unstructured":"Yu L, Tang J, Zhang C, Zeng W, Yan H, Li M, et al. New immunotherapy strategies in breast cancer. Int J Environ Res Public Health. 2017;14(1):68. https:\/\/doi.org\/10.3390\/ijerph14010068.","journal-title":"Int J Environ Res Public Health"},{"issue":"2","key":"3491_CR5","doi-asserted-by":"publisher","first-page":"101042831769222","DOI":"10.1177\/1010428317692226","volume":"39","author":"H Allahyari","year":"2017","unstructured":"Allahyari H, Heidari S, Ghamgosha M, Saffarian P, Amani J. Immunotoxin: a new tool for cancer therapy. Tumor Biology. 2017;39(2):101042831769222. https:\/\/doi.org\/10.1177\/1010428317692226.","journal-title":"Tumor Biology"},{"issue":"23","key":"3491_CR6","doi-asserted-by":"publisher","first-page":"38022","DOI":"10.18632\/oncotarget.16723","volume":"8","author":"R Mokhtari","year":"2017","unstructured":"Mokhtari R, Homayouni T, Baluch N, Morgatskaya E, Kumar S, Das B, et al. Combination therapy in combating cancer. Oncotarget. 2017;8(23):38022\u201343.","journal-title":"Oncotarget"},{"issue":"10","key":"3491_CR7","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1158\/2326-6066.cir-19-0149","volume":"7","author":"A Goodman","year":"2019","unstructured":"Goodman A, Sokol E, Frampton G, Lippman S, Kurzrock R. Microsatellite-stable tumors with high mutational burden benefit from immunotherapy. Cancer Immunol Res. 2019;7(10):1570\u20133. https:\/\/doi.org\/10.1158\/2326-6066.cir-19-0149.","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"3491_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13046-019-1266-0","volume":"38","author":"S Kruger","year":"2019","unstructured":"Kruger S, Ilmer M, Kobold S, Cadilha BL, Endres S, Ormanns S, et al. Advances in cancer immunotherapy 2019\u2013latest trends. J Exp Clin Cancer Res. 2019;38(1):1\u20131.","journal-title":"J Exp Clin Cancer Res"},{"issue":"3","key":"3491_CR9","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/s41573-018-0006-z","volume":"18","author":"R Riley","year":"2019","unstructured":"Riley R, June C, Langer R, Mitchell M. delivery technologies for cancer immunotherapy. Nat Rev Cancer. 2019;18(3):175\u201396. https:\/\/doi.org\/10.1038\/s41573-018-0006-z.","journal-title":"Nat Rev Cancer"},{"key":"3491_CR10","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1200\/EDBK_156572","volume":"35","author":"V Velcheti","year":"2016","unstructured":"Velcheti V, Schalper K. Basic overview of current immunotherapy approaches in cancer. Am Soc Clin Oncol Educ Book. 2016;35:298\u2013308.","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"4","key":"3491_CR11","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.3390\/jcm12041279","volume":"12","author":"Y Gui","year":"2023","unstructured":"Gui Y, He X, Yu J, Jing J. Artificial intelligence-assisted transcriptomic analysis to advance cancer immunotherapy. J Clin Med. 2023;12(4):1279. https:\/\/doi.org\/10.3390\/jcm12041279.","journal-title":"J Clin Med"},{"key":"3491_CR12","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s13045-022-01242-2","volume":"15","author":"M Wu","year":"2022","unstructured":"Wu M, Huang Q, Xie Y, Wu X, Ma H, Zhang Y, et al. Improvement of the anticancer efficacy of PD-1\/PD-L1 blockade via combination therapy and PD-L1 regulation. J Hematol Oncol. 2022;15:24.","journal-title":"J Hematol Oncol"},{"key":"3491_CR13","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1136\/jitc-2022-005644","volume":"10","author":"N Imahashi","year":"2022","unstructured":"Imahashi N, Basar R, Huang Y, Wang F, Baran N, Banerjee PP, et al. Activated B cells suppress T-cell function through metabolic competition. J Immunother Cancer. 2022;10:12.","journal-title":"J Immunother Cancer"},{"key":"3491_CR14","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.1521","author":"X Ren","year":"2024","unstructured":"Ren X, Wang X, Zheng G, Wang S, Wang Q, Yuan M, et al. Targeting one-carbon metabolism for cancer immunotherapy. Clin Translat Med. 2024. https:\/\/doi.org\/10.1002\/ctm2.1521.","journal-title":"Clin Translat Med"},{"issue":"2","key":"3491_CR15","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20201966","volume":"219","author":"M Shakiba","year":"2021","unstructured":"Shakiba M, Zumbo P, Espinosa-Carrasco G, Menocal L, D\u00fcndar F, Carson SE, et al. TCR signal strength defines distinct mechanisms of T cell dysfunction and cancer evasion. J Exp Med. 2021;219(2): e20201966.","journal-title":"J Exp Med"},{"key":"3491_CR16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40425-018-0484-x","volume":"7","author":"M Vugt","year":"2019","unstructured":"Vugt M, Stone GJ, Snyder E, Lipka L, Turner D, et al. Immunogenicity of pembrolizumab in patients with advanced tumors. J Immunother Cancer. 2019;7:1.","journal-title":"J Immunother Cancer"},{"issue":"13","key":"3491_CR17","doi-asserted-by":"publisher","first-page":"2892","DOI":"10.1158\/1078-0432.ccr-14-3061","volume":"21","author":"R Sullivan","year":"2015","unstructured":"Sullivan R, Flaherty K. Pembrolizumab for treatment of patients with advanced or unresectable melanoma. Clin Cancer Res. 2015;21(13):2892\u20137. https:\/\/doi.org\/10.1158\/1078-0432.ccr-14-3061.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"3491_CR18","doi-asserted-by":"publisher","first-page":"323","DOI":"10.31083\/j.ejgo.2020.03.5363","volume":"41","author":"L Roncati","year":"2020","unstructured":"Roncati L, Vadal\u00e0 M, Valentina P, Corazzari V, Palmieri B. Genomic profiling in gynaecological oncology: the future is now! Eur J Gynaecol Oncol. 2020;41(3):323\u20135.","journal-title":"Eur J Gynaecol Oncol"},{"issue":"35","key":"3491_CR19","doi-asserted-by":"publisher","first-page":"4138","DOI":"10.1200\/jco.20.01888","volume":"38","author":"T Kojima","year":"2020","unstructured":"Kojima T, Shah M, Muro K, Fran\u00e7ois \u0395, Adenis A, Hsu C, et al. Randomized phase iii keynote-181 study of pembrolizumab versus chemotherapy in advanced esophageal cancer. J Clin Oncol. 2020;38(35):4138\u201348. https:\/\/doi.org\/10.1200\/jco.20.01888.","journal-title":"J Clin Oncol"},{"issue":"3","key":"3491_CR20","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1093\/annonc\/mdy517","volume":"30","author":"S Adams","year":"2019","unstructured":"Adams S, Schmid P, Rugo H, Winer E, Loirat D, Awada A, et al. Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort a of the phase ii keynote-086 study. Ann Oncol. 2019;30(3):397\u2013404. https:\/\/doi.org\/10.1093\/annonc\/mdy517.","journal-title":"Ann Oncol"},{"issue":"9","key":"3491_CR21","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.4251\/wjgo.v13.i9.1073","volume":"13","author":"R Shotton","year":"2021","unstructured":"Shotton R, Lamarca \u00c1, Valle J, McNamara M. Potential utility of liquid biopsies in the management of patients with biliary tract cancers: a review. World Journal of Gastrointestinal Oncology. 2021;13(9):1073\u201385. https:\/\/doi.org\/10.4251\/wjgo.v13.i9.1073.","journal-title":"World Journal of Gastrointestinal Oncology"},{"key":"3491_CR22","doi-asserted-by":"publisher","first-page":"175628482110244","DOI":"10.1177\/17562848211024460","volume":"14","author":"V Wookey","year":"2021","unstructured":"Wookey V, Grothey A. Update on the role of pembrolizumab in patients with unresectable or metastatic colorectal cancer. Ther Adv Gastroenterol. 2021;14:175628482110244. https:\/\/doi.org\/10.1177\/17562848211024460.","journal-title":"Ther Adv Gastroenterol"},{"issue":"1","key":"3491_CR23","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1111\/imm.13285","volume":"163","author":"E Fakhr","year":"2020","unstructured":"Fakhr E, Modic \u017d, Cid-Arregui \u00c1. Recent developments in immunotherapy of cancers caused by human papillomaviruses. Immunology. 2020;163(1):33\u201345. https:\/\/doi.org\/10.1111\/imm.13285.","journal-title":"Immunology"},{"issue":"12","key":"3491_CR24","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1200\/jco.22.01351","volume":"41","author":"K Ludford","year":"2023","unstructured":"Ludford K, Ho W, Thomas J, Raghav K, Blum M, Fleming N, et al. Neoadjuvant pembrolizumab in localized microsatellite instability high\/deficient mismatch repair solid tumors. J Clin Oncol. 2023;41(12):2181\u201390. https:\/\/doi.org\/10.1200\/jco.22.01351.","journal-title":"J Clin Oncol"},{"issue":"17","key":"3491_CR25","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1200\/jco.18.01265","volume":"37","author":"H Chung","year":"2019","unstructured":"Chung H, Ros W, Delord J, Perets R, Italiano A, Shapira-Frommer R, et al. Efficacy and safety of pembrolizumab in previously treated advanced cervical cancer: results from the phase ii keynote-158 study. J Clin Oncol. 2019;37(17):1470\u20138. https:\/\/doi.org\/10.1200\/jco.18.01265.","journal-title":"J Clin Oncol"},{"key":"3491_CR26","doi-asserted-by":"publisher","first-page":"4297","DOI":"10.2147\/cmar.s151023","volume":"11","author":"P Rusquec","year":"2019","unstructured":"Rusquec P, Calbiac O, Robert M, Campone M, Frenel J. <p>clinical utility of pembrolizumab in the management of advanced solid tumors: an evidence-based review on the emerging new data<\/p>. Cancer Manag Res. 2019;11:4297\u2013312. https:\/\/doi.org\/10.2147\/cmar.s151023.","journal-title":"Cancer Manag Res"},{"key":"3491_CR27","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.ejca.2020.11.010","volume":"144","author":"C Robert","year":"2021","unstructured":"Robert C, Hwu W, Hamid O, Ribas A, Weber J, Daud A, et al. Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: a landmark analysis in patients with advanced melanoma. Eur J Cancer. 2021;144:182\u201391. https:\/\/doi.org\/10.1016\/j.ejca.2020.11.010.","journal-title":"Eur J Cancer"},{"issue":"19","key":"3491_CR28","doi-asserted-by":"publisher","first-page":"4286","DOI":"10.1158\/1078-0432.ccr-14-2607","volume":"21","author":"A Patnaik","year":"2015","unstructured":"Patnaik A, Kang S, Rasco D, Papadopoulos K, Elassaiss-Schaap J, Beeram M, et al. Phase i study of pembrolizumab (mk-3475; anti\u2013pd-1 monoclonal antibody) in patients with advanced solid tumors. Clin Cancer Res. 2015;21(19):4286\u201393. https:\/\/doi.org\/10.1158\/1078-0432.ccr-14-2607.","journal-title":"Clin Cancer Res"},{"issue":"13","key":"3491_CR29","doi-asserted-by":"publisher","first-page":"1044327","DOI":"10.3389\/fonc.2023.1044327","volume":"7","author":"B Yang","year":"2023","unstructured":"Yang B, Wang B, Chen Y, Wan N, Xie F, Yang N, et al. Effectiveness and safety of pembrolizumab for patients with advanced non-small cell lung cancer in real-world studies and randomized controlled trials: A systematic review and meta-analysis. Front Oncol. 2023;7(13):1044327.","journal-title":"Front Oncol"},{"issue":"5","key":"3491_CR30","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s10928-017-9528-y","volume":"44","author":"H Li","year":"2017","unstructured":"Li H, Yu J, Liu C, Liu J, Subramaniam S, Zhao H, et al. Time dependent pharmacokinetics of pembrolizumab in patients with solid tumor and its correlation with best overall response. J Pharmacokinet Pharmacodyn. 2017;44(5):403\u201314. https:\/\/doi.org\/10.1007\/s10928-017-9528-y.","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"11","key":"3491_CR31","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1111\/1759-7714.13197","volume":"10","author":"A Osa","year":"2019","unstructured":"Osa A, Uenami T, Naito Y, Hirata H, Koyama S, Takimoto T, et al. Monitoring antibody binding to t cells in a pembrolizumab-treated patient with lung adenocarcinoma on hemodialysis. Thoracic Cancer. 2019;10(11):2183\u20137. https:\/\/doi.org\/10.1111\/1759-7714.13197.","journal-title":"Thoracic Cancer"},{"issue":"11","key":"3491_CR32","doi-asserted-by":"publisher","first-page":"8686","DOI":"10.3390\/curroncol29110685","volume":"29","author":"L Jones","year":"2022","unstructured":"Jones L, Rittberg R, Leung B, Shokoohi A, Pender A, Wong S, et al. Alternate pembrolizumab dosing interval in advanced nsclc with pd-l1 tps \u2265 50%: 3 weekly compared to 6 weekly dosing. Curr Oncol. 2022;29(11):8686\u201392. https:\/\/doi.org\/10.3390\/curroncol29110685.","journal-title":"Curr Oncol"},{"issue":"3","key":"3491_CR33","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.3390\/curroncol28030152","volume":"28","author":"S Vermeulen","year":"2021","unstructured":"Vermeulen S, Awada G, Keyaerts M, Neyns B, Everaert H. Early reassessment of total metabolic tumor volume on fdg-pet\/ct in advanced melanoma patients treated with pembrolizumab predicts long-term outcome. Curr Oncol. 2021;28(3):1630\u201340. https:\/\/doi.org\/10.3390\/curroncol28030152.","journal-title":"Curr Oncol"},{"key":"3491_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-71735-y","author":"O Yamaguchi","year":"2020","unstructured":"Yamaguchi O, Kaira K, Hashimoto K, Mouri A, Shiono A, Miura Y, et al. Tumor metabolic volume by 18f-fdg-pet as a prognostic predictor of first-line pembrolizumab for nsclc patients with pd-l1 \u2265 50%. Scie Rep. 2020. https:\/\/doi.org\/10.1038\/s41598-020-71735-y.","journal-title":"Scie Rep"},{"issue":"6","key":"3491_CR35","doi-asserted-by":"publisher","first-page":"6603","DOI":"10.1002\/cam4.5434","volume":"12","author":"D Pfister","year":"2022","unstructured":"Pfister D, Haddad R, Worden F, Weiss J, Mehra R, Chow L, et al. Biomarkers predictive of response to pembrolizumab in head and neck cancer. Cancer Med. 2022;12(6):6603\u201314. https:\/\/doi.org\/10.1002\/cam4.5434.","journal-title":"Cancer Med"},{"issue":"4","key":"3491_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3126\/ajms.v14i4.52811","volume":"14","author":"R Dhar","year":"2023","unstructured":"Dhar R, Kumar A, Karmakar S. Checkmate with checkpoint inhibitors: new paradigm in immunotherapy. As J Med Sci. 2023;14(4):1\u20132. https:\/\/doi.org\/10.3126\/ajms.v14i4.52811.","journal-title":"As J Med Sci"},{"issue":"2","key":"3491_CR37","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1042\/cs20181003","volume":"133","author":"J Inthagard","year":"2019","unstructured":"Inthagard J, Edwards J, Roseweir A. Immunotherapy: enhancing the efficacy of this promising therapeutic in multiple cancers. Clin Sci. 2019;133(2):181\u201393. https:\/\/doi.org\/10.1042\/cs20181003.","journal-title":"Clin Sci"},{"key":"3491_CR38","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00167","author":"M Khan","year":"2020","unstructured":"Khan M, Arooj S, Wang H. Nk cell-based immune checkpoint inhibition. Front Immunol. 2020. https:\/\/doi.org\/10.3389\/fimmu.2020.00167.","journal-title":"Front Immunol"},{"issue":"3","key":"3491_CR39","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1007\/s00262-020-02717-2","volume":"70","author":"A Safarzadeh","year":"2020","unstructured":"Safarzadeh A, Alizadeh M, Beyranvand F, Jozaaee R, Hajiasgharzadeh K, Baghbanzadeh A, et al. Varied functions of immune checkpoints during cancer metastasis. Cancer Immunol Immunother. 2020;70(3):569\u201388. https:\/\/doi.org\/10.1007\/s00262-020-02717-2.","journal-title":"Cancer Immunol Immunother"},{"issue":"4","key":"3491_CR40","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1124\/pr.116.012682","volume":"68","author":"G Alatrash","year":"2016","unstructured":"Alatrash G, Daver N, Mittendorf E. Targeting immune checkpoints in hematologic malignancies. Pharmacol Rev. 2016;68(4):1014\u201325. https:\/\/doi.org\/10.1124\/pr.116.012682.","journal-title":"Pharmacol Rev"},{"issue":"1","key":"3491_CR41","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1002\/bab.2081","volume":"69","author":"S Behravesh","year":"2020","unstructured":"Behravesh S, Shomali N, Danbaran G, Aslani S, Hemmatzadeh M, Hosseinzadeh R, et al. Cardiotoxicity of immune checkpoint inhibitors: an updated review. Biotechnol Appl Biochem. 2020;69(1):61\u20139. https:\/\/doi.org\/10.1002\/bab.2081.","journal-title":"Biotechnol Appl Biochem"},{"issue":"1","key":"3491_CR42","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1111\/imr.12527","volume":"276","author":"H Matlung","year":"2017","unstructured":"Matlung H, Szilagyi K, Barclay N, Berg T. The cd47-sirp\u03b1 signaling axis as an innate immune checkpoint in cancer. Immunol Rev. 2017;276(1):145\u201364. https:\/\/doi.org\/10.1111\/imr.12527.","journal-title":"Immunol Rev"},{"issue":"14","key":"3491_CR43","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1200\/jco.19.03136","volume":"38","author":"S Gadgeel","year":"2020","unstructured":"Gadgeel S, Rodr\u00edguez-Abreu D, Speranza G, Esteban E, Felip E, D\u00f3mine M, et al. Updated analysis from keynote-189: pembrolizumab or placebo plus pemetrexed and platinum for previously untreated metastatic nonsquamous non\u2013small-cell lung cancer. J Clin Oncol. 2020;38(14):1505\u201317. https:\/\/doi.org\/10.1200\/jco.19.03136.","journal-title":"J Clin Oncol"},{"issue":"12","key":"3491_CR44","doi-asserted-by":"publisher","first-page":"3158","DOI":"10.1158\/1078-0432.ccr-16-1761","volume":"23","author":"J Yearley","year":"2017","unstructured":"Yearley J, Gibson C, Yu N, Moon C, Murphy E, Juco J, et al. Pd-l2 expression in human tumors: relevance to anti-pd-1 therapy in cancer. Clin Cancer Res. 2017;23(12):3158\u201367. https:\/\/doi.org\/10.1158\/1078-0432.ccr-16-1761.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"3491_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40880-019-0376-6","volume":"39","author":"T Larsen","year":"2019","unstructured":"Larsen T, Hussmann D, Nielsen A. pd-l1 and pd-l2 expression correlated genes in non-small-cell lung cancer. Cancer Commun. 2019;39(1):1\u201314. https:\/\/doi.org\/10.1186\/s40880-019-0376-6.","journal-title":"Cancer Commun"},{"issue":"3","key":"3491_CR46","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1111\/cei.12921","volume":"188","author":"Q Jiao","year":"2017","unstructured":"Jiao Q, Liu C, Li W, Fang F, Qian Q, Zhang X. Programmed death-1 ligands 1 and 2 expression in cutaneous squamous cell carcinoma and their relationship with tumour- infiltrating dendritic cells. Clin Exp Immunol. 2017;188(3):420\u20139. https:\/\/doi.org\/10.1111\/cei.12921.","journal-title":"Clin Exp Immunol"},{"issue":"5","key":"3491_CR47","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1177\/1078155220924084","volume":"26","author":"E Yeked\u00fcz","year":"2020","unstructured":"Yeked\u00fcz E, Dursun B, Ayd\u0131n G, Yazgan S, \u00d6zt\u00fcrk H, Azap A, et al. Clinical course of covid-19 infection in elderly patient with melanoma on nivolumab. J Oncol Pharm Pract. 2020;26(5):1289\u201394. https:\/\/doi.org\/10.1177\/1078155220924084.","journal-title":"J Oncol Pharm Pract"},{"issue":"21","key":"3491_CR48","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1056\/nejmoa1810865","volume":"379","author":"L Paz-Ares","year":"2018","unstructured":"Paz-Ares L, Luft A, Vicente D, Tafreshi A, G\u00fcm\u00fc\u015f M, Mazi\u00e8res J, et al. Pembrolizumab plus chemotherapy for squamous non\u2013small-cell lung cancer. N Engl J Med. 2018;379(21):2040\u201351. https:\/\/doi.org\/10.1056\/nejmoa1810865.","journal-title":"N Engl J Med"},{"issue":"12","key":"3491_CR49","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1016\/j.clon.2019.07.003","volume":"31","author":"S Otter","year":"2019","unstructured":"Otter S, Chatterjee J, Stewart A, Michael A. The role of biomarkers for the prediction of response to checkpoint immunotherapy and the rationale for the use of checkpoint immunotherapy in cervical cancer. Clin Oncol. 2019;31(12):834\u201343. https:\/\/doi.org\/10.1016\/j.clon.2019.07.003.","journal-title":"Clin Oncol"},{"issue":"11","key":"3491_CR50","doi-asserted-by":"publisher","first-page":"3595","DOI":"10.3390\/ijms19113595","volume":"19","author":"F Papaccio","year":"2018","unstructured":"Papaccio F, Corte C, Viscardi G, Liello R, Esposito G, Sparano F, et al. Hgf\/met and the immune system: relevance for cancer immunotherapy. Int J Mol Sci. 2018;19(11):3595. https:\/\/doi.org\/10.3390\/ijms19113595.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"3491_CR51","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/nejmoa1411087","volume":"372","author":"S Ansell","year":"2015","unstructured":"Ansell S, Lesokhin A, Borrello I, Halwani A, Scott E, Gutierrez M, et al. Pd-1 blockade with nivolumab in relapsed or refractory hodgkin\u2019s lymphoma. N Engl J Med. 2015;372(4):311\u20139. https:\/\/doi.org\/10.1056\/nejmoa1411087.","journal-title":"N Engl J Med"},{"issue":"4","key":"3491_CR52","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1093\/annonc\/mdz011","volume":"30","author":"O Hamid","year":"2019","unstructured":"Hamid O, Robert C, Daud A, Hodi F, Hwu W, Kefford R, et al. Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in keynote-001. Ann Oncol. 2019;30(4):582\u20138. https:\/\/doi.org\/10.1093\/annonc\/mdz011.","journal-title":"Ann Oncol"},{"issue":"26","key":"3491_CR53","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1056\/nejmoa1500596","volume":"372","author":"D Le","year":"2015","unstructured":"Le D, Uram J, Wang H, Bartlett B, Kemberling H, Eyring A, et al. Pd-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372(26):2509\u201320. https:\/\/doi.org\/10.1056\/nejmoa1500596.","journal-title":"N Engl J Med"},{"issue":"4","key":"3491_CR54","doi-asserted-by":"publisher","first-page":"315","DOI":"10.3322\/caac.21665","volume":"71","author":"E Butler","year":"2021","unstructured":"Butler E, Ludwig K, Pacenta H, Klesse L, Watt T, Laetsch T. Recent progress in the treatment of cancer in children. CA Cancer J Clin. 2021;71(4):315\u201332. https:\/\/doi.org\/10.3322\/caac.21665.","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"3491_CR55","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1007\/s40272-021-00461-3","volume":"23","author":"A Tragiannidis","year":"2021","unstructured":"Tragiannidis A, Groll A. Secondary dysgammaglobulinemia in children with hematological malignancies treated with targeted therapies. Pediatr Drugs. 2021;23(5):445\u201355. https:\/\/doi.org\/10.1007\/s40272-021-00461-3.","journal-title":"Pediatr Drugs"},{"key":"3491_CR56","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-020-79139-8","volume":"11","author":"Santeon NSCLC Study Group","year":"2021","unstructured":"Santeon NSCLC Study Group. Real-world outcomes versus clinical trial results of immunotherapy in stage IV non-small cell lung cancer (NSCLC) in the Netherlands. Scie Rep. 2021;11:1.","journal-title":"Scie Rep"},{"key":"3491_CR57","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000016834","author":"M Yamasaki","year":"2019","unstructured":"Yamasaki M, Funaishi K, Kawamoto K, Mu Y, Matsumoto N, Taniwaki M, et al. Platinum-doublet chemotherapy followed by pembrolizumab therapy for lung cancer with lymphangitis carcinomatosa mimicking interstitial pneumonitis. Medicine. 2019. https:\/\/doi.org\/10.1097\/md.0000000000016834.","journal-title":"Medicine"},{"issue":"2","key":"3491_CR58","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1001\/jamaoncol.2022.6705","volume":"9","author":"X Zhang","year":"2023","unstructured":"Zhang X, Ning C, Zhao H. Tissue-based pd-l1 expression is the strongest predictor of overall survival benefit from ici in advanced gastroesophageal cancer. JAMA Oncol. 2023;9(2):280. https:\/\/doi.org\/10.1001\/jamaoncol.2022.6705.","journal-title":"JAMA Oncol"},{"issue":"9","key":"3491_CR59","doi-asserted-by":"publisher","first-page":"727","DOI":"10.2217\/imt-2021-0019","volume":"13","author":"S Mandrekar","year":"2021","unstructured":"Mandrekar S, Kozono D, Oxnard G, Hillman S, Wigle D, Govindan R, et al. Integration of immunotherapy into adjuvant therapy for resected non-small-cell lung cancer: alchemist chemo-io (accio). Immunotherapy. 2021;13(9):727\u201334. https:\/\/doi.org\/10.2217\/imt-2021-0019.","journal-title":"Immunotherapy"},{"issue":"21","key":"3491_CR60","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.1200\/JCO.21.00174","volume":"39","author":"M Reck","year":"2021","unstructured":"Reck M, Rodr\u00edguez-Abreu D, Robinson AG, Hui R, Cs\u0151szi T, F\u00fcl\u00f6p A, et al. Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non\u2013small-cell lung cancer with PD-L1 tumor proportion score\u2265 50%. J Clin Oncol. 2021;39(21):2339.","journal-title":"J Clin Oncol"},{"issue":"4","key":"3491_CR61","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1200\/jco.21.02508","volume":"41","author":"K Harrington","year":"2023","unstructured":"Harrington K, Burtness B, Greil R, Souli\u00e8res D, Tahara M, Castro G, et al. Pembrolizumab with or without chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma: updated results of the phase iii keynote-048 study. J Clin Oncol. 2023;41(4):790\u2013802. https:\/\/doi.org\/10.1200\/jco.21.02508.","journal-title":"J Clin Oncol"},{"issue":"21","key":"3491_CR62","doi-asserted-by":"publisher","first-page":"2321","DOI":"10.1200\/jco.21.02198","volume":"40","author":"B Burtness","year":"2022","unstructured":"Burtness B, Rischin D, Greil R, Souli\u00e8res D, Tahara M, Castro G, et al. Pembrolizumab alone or with chemotherapy for recurrent\/metastatic head and neck squamous cell carcinoma in keynote-048: subgroup analysis by programmed death ligand-1 combined positive score. J Clin Oncol. 2022;40(21):2321\u201332. https:\/\/doi.org\/10.1200\/jco.21.02198.","journal-title":"J Clin Oncol"},{"issue":"10142","key":"3491_CR63","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/s0140-6736(18)31257-1","volume":"392","author":"K Shitara","year":"2018","unstructured":"Shitara K, \u00d6zg\u00fcro\u01e7lu M, Bang Y, Bartolomeo M, Mandal\u00e0 M, Ryu M, et al. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (keynote-061): a randomised, open-label, controlled, phase 3 trial. The Lancet. 2018;392(10142):123\u201333. https:\/\/doi.org\/10.1016\/s0140-6736(18)31257-1.","journal-title":"The Lancet"},{"key":"3491_CR64","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2021.102219","author":"J Lonie","year":"2021","unstructured":"Lonie J, Barbour A, Dolcetti R. Understanding the immuno-biology of oesophageal adenocarcinoma: towards improved therapeutic approaches. Cancer Treat Rev. 2021. https:\/\/doi.org\/10.1016\/j.ctrv.2021.102219.","journal-title":"Cancer Treat Rev"},{"issue":"2","key":"3491_CR65","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1111\/his.14924","volume":"83","author":"S Yamashita","year":"2023","unstructured":"Yamashita S, Ab\u00e9 H, Yamashita H, Yagi K, Seto Y, Ushiku T. pd-l1 and hla-class i expression status and their therapeutic implication in oesophageal small-cell carcinoma. Histopathology. 2023;83(2):264\u201375. https:\/\/doi.org\/10.1111\/his.14924.","journal-title":"Histopathology"},{"issue":"21","key":"3491_CR66","doi-asserted-by":"publisher","first-page":"2460","DOI":"10.1200\/jco.2015.64.8931","volume":"34","author":"R Nanda","year":"2016","unstructured":"Nanda R, Chow L, Dees C, Berger R, Gupta S, Geva R, et al. Pembrolizumab in patients with advanced triple-negative breast cancer: phase ib keynote-012 study. J Clin Oncol. 2016;34(21):2460\u20137. https:\/\/doi.org\/10.1200\/jco.2015.64.8931.","journal-title":"J Clin Oncol"},{"key":"3491_CR67","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyac014","author":"A Jacobson","year":"2022","unstructured":"Jacobson A. Pembrolizumab improves outcomes in early-stage and locally advanced or metastatic triple-negative breast cancer. Oncologist. 2022. https:\/\/doi.org\/10.1093\/oncolo\/oyac014.","journal-title":"Oncologist"},{"issue":"8","key":"3491_CR68","doi-asserted-by":"publisher","first-page":"2190","DOI":"10.1002\/ijc.33013","volume":"147","author":"S Piha-Paul","year":"2020","unstructured":"Piha-Paul S, Oh D, Ueno M, Malka D, Chung H, Nagrial A, et al. Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: results from the keynote-158 and keynote-028 studies. Int J Cancer. 2020;147(8):2190\u20138. https:\/\/doi.org\/10.1002\/ijc.33013.","journal-title":"Int J Cancer"},{"issue":"17","key":"3491_CR69","doi-asserted-by":"publisher","first-page":"4323","DOI":"10.3390\/cancers14174323","volume":"14","author":"C Park","year":"2022","unstructured":"Park C, Sung M, Kim S, Jo J, Lee H, Chung M, et al. Prognostic factors in patients treated with pembrolizumab as a second-line treatment for advanced biliary tract cancer. Cancers. 2022;14(17):4323. https:\/\/doi.org\/10.3390\/cancers14174323.","journal-title":"Cancers"},{"issue":"17","key":"3491_CR70","doi-asserted-by":"publisher","first-page":"4229","DOI":"10.3390\/cancers14174229","volume":"14","author":"G Leem","year":"2022","unstructured":"Leem G, Jang S, Cho J, Jo J, Lee H, Chung M, et al. Safety and efficacy of allogeneic natural killer cells in combination with pembrolizumab in patients with chemotherapy-refractory biliary tract cancer: a multicenter open-label phase 1\/2a trial. Cancers. 2022;14(17):4229. https:\/\/doi.org\/10.3390\/cancers14174229.","journal-title":"Cancers"},{"key":"3491_CR71","doi-asserted-by":"publisher","first-page":"7295","DOI":"10.2147\/ott.s167645","volume":"11","author":"P Salman","year":"2018","unstructured":"Salman P, Panay S, Fern\u00e1ndez R, Mahave M, Soza-Ried C. Evidence of response to pembrolizumab in a patient with lynch syndrome-related metastatic colon cancer. Onco Targets Ther. 2018;11:7295\u2013300. https:\/\/doi.org\/10.2147\/ott.s167645.","journal-title":"Onco Targets Ther"},{"key":"3491_CR72","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.2147\/ott.s300987","volume":"14","author":"J Chen","year":"2021","unstructured":"Chen J, Lou H. Complete response to pembrolizumab in advanced colon cancer harboring somatic pole f367s mutation with microsatellite stability status: a case study. Onco Targets Ther. 2021;14:1791\u20136. https:\/\/doi.org\/10.2147\/ott.s300987.","journal-title":"Onco Targets Ther"},{"issue":"2","key":"3491_CR73","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1002\/ags3.12633","volume":"7","author":"Y Miyamoto","year":"2022","unstructured":"Miyamoto Y, Ogawa K, Ohuchi M, Tokunaga R, Baba H. Emerging evidence of immunotherapy for colorectal cancer. Ann Gastroenterol Surg. 2022;7(2):216\u201324. https:\/\/doi.org\/10.1002\/ags3.12633.","journal-title":"Ann Gastroenterol Surg"},{"issue":"26","key":"3491_CR74","doi-asserted-by":"publisher","first-page":"2981","DOI":"10.1200\/jco.19.02627","volume":"38","author":"V Makker","year":"2020","unstructured":"Makker V, Taylor M, Aghajanian C, Oaknin A, Mier J, Cohn A, et al. Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer. J Clin Oncol. 2020;38(26):2981\u201392. https:\/\/doi.org\/10.1200\/jco.19.02627.","journal-title":"J Clin Oncol"},{"issue":"1","key":"3491_CR75","doi-asserted-by":"publisher","first-page":"24","DOI":"10.3390\/life12010024","volume":"12","author":"N Kathuria-Prakash","year":"2021","unstructured":"Kathuria-Prakash N, Drolen C, Hannigan C, Drakaki A. Immunotherapy and metastatic renal cell carcinoma: a review of new treatment approaches. Life. 2021;12(1):24. https:\/\/doi.org\/10.3390\/life12010024.","journal-title":"Life"},{"issue":"8","key":"3491_CR76","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1056\/nejmoa2106391","volume":"385","author":"T Choueiri","year":"2021","unstructured":"Choueiri T, Tomczak P, Park S, Venugopal B, Ferguson T, Chang Y, et al. Adjuvant pembrolizumab after nephrectomy in renal-cell carcinoma. N Engl J Med. 2021;385(8):683\u201394. https:\/\/doi.org\/10.1056\/nejmoa2106391.","journal-title":"N Engl J Med"},{"issue":"1","key":"3491_CR77","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1007\/s10147-021-02014-7","volume":"27","author":"S Tamada","year":"2021","unstructured":"Tamada S, Kondoh C, Matsubara N, Mizuno R, Kimura G, Anai S, et al. Pembrolizumab plus axitinib versus sunitinib in metastatic renal cell carcinoma: outcomes of japanese patients enrolled in the randomized, phase iii, open-label keynote-426 study. Int J Clin Oncol. 2021;27(1):154\u201364. https:\/\/doi.org\/10.1007\/s10147-021-02014-7.","journal-title":"Int J Clin Oncol"},{"issue":"10","key":"3491_CR78","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.16144","volume":"3","author":"T Watson","year":"2020","unstructured":"Watson T, G\u00e0o X, Reynolds K, Kong C. Cost-effectiveness of pembrolizumab plus axitinib vs nivolumab plus ipilimumab as first-line treatment of advanced renal cell carcinoma in the us. JAMA Netw Open. 2020;3(10): e2016144. https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.16144.","journal-title":"JAMA Netw Open"},{"issue":"3","key":"3491_CR79","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1159\/000519855","volume":"14","author":"Y Kawasaki","year":"2021","unstructured":"Kawasaki Y, Tanaka K, Nakayama D, Katayama H, Shimada S, Satake Y, et al. Combination therapy of pembrolizumab plus axitinib for a patient on hemodialysis with metastatic renal cell carcinoma: a case report. Case Reports in Oncology. 2021;14(3):1522\u20139. https:\/\/doi.org\/10.1159\/000519855.","journal-title":"Case Reports in Oncology"},{"key":"3491_CR80","doi-asserted-by":"publisher","DOI":"10.1016\/j.gore.2021.100831","author":"K Miller","year":"2021","unstructured":"Miller K, Filippova O, Hayes S, Abu-Rustum N, Aghajanian C, Broach V, et al. Pattern of disease and response to pembrolizumab in recurrent cervical cancer. Gynecol Oncol Rep. 2021. https:\/\/doi.org\/10.1016\/j.gore.2021.100831.","journal-title":"Gynecol Oncol Rep"},{"key":"3491_CR81","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.gore.2018.01.009","volume":"24","author":"N Ngoi","year":"2018","unstructured":"Ngoi N, Heong V, Lee X, Huang Y, Thian Y, Choo B, et al. Tumor molecular profiling of responders and non-responders following pembrolizumab monotherapy in chemotherapy resistant advanced cervical cancer. Gynecol Oncol Rep. 2018;24:1\u20135. https:\/\/doi.org\/10.1016\/j.gore.2018.01.009.","journal-title":"Gynecol Oncol Rep"},{"issue":"5","key":"3491_CR82","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1248\/bpb.b21-00939","volume":"45","author":"Y Kunimitsu","year":"2022","unstructured":"Kunimitsu Y, Morio K, Hirata S, Yamamoto K, Omura T, Hara T, et al. Effects of proton pump inhibitors on survival outcomes in patients with metastatic or unresectable urothelial carcinoma treated with pembrolizumab. Biol Pharm Bull. 2022;45(5):590\u20135. https:\/\/doi.org\/10.1248\/bpb.b21-00939.","journal-title":"Biol Pharm Bull"},{"key":"3491_CR83","doi-asserted-by":"publisher","first-page":"331","DOI":"10.54097\/hset.v36i.5700","volume":"36","author":"W Cui","year":"2023","unstructured":"Cui W. The usage of pembrolizumab in metastatic urothelial carcinoma. Highlig Sci Eng Technol. 2023;36:331\u201340.","journal-title":"Highlig Sci Eng Technol"},{"issue":"11","key":"3491_CR84","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1056\/nejmoa1613683","volume":"376","author":"J Bellmunt","year":"2017","unstructured":"Bellmunt J, Wit R, Vaughn D, Fradet Y, Lee J, Fong L, et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med. 2017;376(11):1015\u201326. https:\/\/doi.org\/10.1056\/nejmoa1613683.","journal-title":"N Engl J Med"},{"issue":"1","key":"3491_CR85","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1159\/000521979","volume":"15","author":"M Vitorino","year":"2022","unstructured":"Vitorino M, Santos C. Use of pembrolizumab in end-stage renal disease: a case report with complete response. Case Reports in Oncology. 2022;15(1):187\u201390. https:\/\/doi.org\/10.1159\/000521979.","journal-title":"Case Reports in Oncology"},{"issue":"9","key":"3491_CR86","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.6004\/jnccn.2018.0072","volume":"16","author":"T Flaig","year":"2018","unstructured":"Flaig T, Spiess P, Agarwal N, Bangs R, Boorjian S, Buyyounouski M, et al. Nccn guidelines insights: bladder cancer, version 52018. J Nat Comprehen Cancer Network. 2018;16(9):1041\u201353.","journal-title":"J Nat Comprehen Cancer Network"},{"issue":"5","key":"3491_CR87","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1158\/2326-6066.cir-18-0890","volume":"7","author":"S Ansell","year":"2019","unstructured":"Ansell S. The highs and lows of immune-checkpoint blockade in lymphoma. Cancer Immunol Res. 2019;7(5):696\u2013700. https:\/\/doi.org\/10.1158\/2326-6066.cir-18-0890.","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"3491_CR88","doi-asserted-by":"publisher","DOI":"10.1097\/hs9.0000000000000020","volume":"2","author":"R Moy","year":"2018","unstructured":"Moy R, Younes A. Immune checkpoint inhibition in hodgkin lymphoma. Hemasphere. 2018;2(1): e20. https:\/\/doi.org\/10.1097\/hs9.0000000000000020.","journal-title":"Hemasphere"},{"key":"3491_CR89","doi-asserted-by":"publisher","unstructured":"Pembrolizumab Improves Progression-Free Survival in Relapsed\/Refractory Hodgkin Lymphoma. Oncologist. 2020 Jul;25 Suppl 1(Suppl 1):S18-S19. https:\/\/doi.org\/10.1634\/theoncologist.2020-0561.","DOI":"10.1634\/theoncologist.2020-0561"},{"key":"3491_CR90","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2019\/9513701","volume":"2019","author":"D Goycoechea","year":"2019","unstructured":"Goycoechea D, Stalder G, Martins F, Duchosal M. Immune checkpoint inhibition in classical hodgkin lymphoma: from early achievements towards new perspectives. Journal of Oncology. 2019;2019:1\u201316. https:\/\/doi.org\/10.1155\/2019\/9513701.","journal-title":"Journal of Oncology"},{"issue":"19","key":"3491_CR91","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1056\/nejmoa1802357","volume":"378","author":"A Eggermont","year":"2018","unstructured":"Eggermont A, Blank C, Mandal\u00e0 M, Long G, Atkinson V, Dalle S, et al. Adjuvant pembrolizumab versus placebo in resected stage iii melanoma. N Engl J Med. 2018;378(19):1789\u2013801. https:\/\/doi.org\/10.1056\/nejmoa1802357.","journal-title":"N Engl J Med"},{"issue":"4","key":"3491_CR92","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1007\/s42399-020-00253-9","volume":"2","author":"S Anahid","year":"2020","unstructured":"Anahid S, Afra O. The combination of radiotherapy with pembrolizumab in the treatment of metastatic melanoma patients: a systematic review. SN Compreh Clin Med. 2020;2(4):432\u20138. https:\/\/doi.org\/10.1007\/s42399-020-00253-9.","journal-title":"SN Compreh Clin Med"},{"issue":"11","key":"3491_CR93","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1111\/1346-8138.16518","volume":"49","author":"N Yamazaki","year":"2022","unstructured":"Yamazaki N, Shimizu A, Ozaki M, Hamada M, Takeuchi N, Ito Y, et al. Real-world safety and effectiveness of pembrolizumab in japanese patients with radically unresectable melanoma: an all-case postmarketing surveillance in japan. J Dermatol. 2022;49(11):1096\u2013105. https:\/\/doi.org\/10.1111\/1346-8138.16518.","journal-title":"J Dermatol"},{"issue":"3","key":"3491_CR94","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1097\/cmr.0000000000000885","volume":"33","author":"B Cybulska-Stopa","year":"2023","unstructured":"Cybulska-Stopa B, Piejko K, Ostaszewski K, Dziura R, Galus \u0141, Zi\u00f3\u0142kowska B, et al. Long-term clinical evidence of comparable efficacy and toxicity of nivolumab and pembrolizumab in advanced melanoma treatment. Melanoma Res. 2023;33(3):208\u201317. https:\/\/doi.org\/10.1097\/cmr.0000000000000885.","journal-title":"Melanoma Res"},{"issue":"13","key":"3491_CR95","doi-asserted-by":"publisher","first-page":"3753","DOI":"10.1158\/1078-0432.ccr-18-4070","volume":"25","author":"L Marcus","year":"2019","unstructured":"Marcus L, Lemery S, Keegan P, Pazdur R. FDA approval summary: pembrolizumab for the treatment of microsatellite instability-high solid tumors. Clin Cancer Res. 2019;25(13):3753\u20138. https:\/\/doi.org\/10.1158\/1078-0432.ccr-18-4070.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"3491_CR96","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1002\/cpt.1946","volume":"109","author":"N Seligson","year":"2020","unstructured":"Seligson N, Knepper T, Ragg S, Walko C. Developing drugs for tissue-agnostic indications: a paradigm shift in leveraging cancer biology for precision medicine. Clin Pharmacol Ther. 2020;109(2):334\u201342. https:\/\/doi.org\/10.1002\/cpt.1946.","journal-title":"Clin Pharmacol Ther"},{"key":"3491_CR97","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-021-00870-z","author":"F Pecci","year":"2021","unstructured":"Pecci F, Cantini L, Bittoni A, Lenci E, Lupi A, Crocetti S, et al. Beyond microsatellite instability: evolving strategies integrating immunotherapy for microsatellite stable colorectal cancer. Curr Treatment Opt Oncol. 2021. https:\/\/doi.org\/10.1007\/s11864-021-00870-z.","journal-title":"Curr Treatment Opt Oncol"},{"issue":"23","key":"3491_CR98","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1056\/NEJMoa2017699","volume":"383","author":"T Andr\u00e9","year":"2020","unstructured":"Andr\u00e9 T, Shiu KK, Kim TW, Jensen BV, Jensen LH, Punt C, Smith D, Garcia-Carbonero R, Benavides M, Gibbs P, de la Fouchardiere C. Pembrolizumab in microsatellite-instability\u2013high advanced colorectal cancer. N Engl J Med. 2020;383(23):2207\u201318.","journal-title":"N Engl J Med"},{"issue":"2","key":"3491_CR99","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1002\/cpt.1946","volume":"109","author":"ND Seligson","year":"2021","unstructured":"Seligson ND, Knepper TC, Ragg S, Walko CM. Developing drugs for tissue-agnostic indications: a paradigm shift in leveraging cancer biology for precision medicine. Clin Pharmacol Ther. 2021;109(2):334\u201342.","journal-title":"Clin Pharmacol Ther"},{"key":"3491_CR100","doi-asserted-by":"publisher","unstructured":"CADTH Reimbursement Review - Pembrolizumab (keytruda). Canadian Journal of Health Technologies 2023;3(2). https:\/\/doi.org\/10.51731\/cjht.2023.561.","DOI":"10.51731\/cjht.2023.561"},{"issue":"4","key":"3491_CR101","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1111\/neup.12729","volume":"41","author":"T Kurashige","year":"2021","unstructured":"Kurashige T, Mito M, Yamamoto H, Sugiura T, Onoe T, Kuraoka K, et al. pembrolizumab-caused polyradiculoneuropathy as an immune-related adverse event. Neuropathology. 2021;41(4):266\u201372. https:\/\/doi.org\/10.1111\/neup.12729.","journal-title":"Neuropathology"},{"issue":"6","key":"3491_CR102","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1007\/s40259-016-0204-3","volume":"30","author":"D Day","year":"2016","unstructured":"Day D, Hansen A. Immune-related adverse events associated with immune checkpoint inhibitors. BioDrugs. 2016;30(6):571\u201384. https:\/\/doi.org\/10.1007\/s40259-016-0204-3.","journal-title":"BioDrugs"},{"key":"3491_CR103","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.28393","author":"M Baldawi","year":"2022","unstructured":"Baldawi M, Dhami B, Gosai J, Al-Khafaji R. Adverse endocrine-related effects of pembrolizumab precipitating severe hyponatremia. Cureus. 2022. https:\/\/doi.org\/10.7759\/cureus.28393.","journal-title":"Cureus"},{"issue":"4","key":"3491_CR104","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1097\/cmr.0000000000000759","volume":"31","author":"J Finsterer","year":"2021","unstructured":"Finsterer J. Pembrolizumab-induced hypothyroidism manifesting as myopathy and psychosis. Melanoma Res. 2021;31(4):405\u20136. https:\/\/doi.org\/10.1097\/cmr.0000000000000759.","journal-title":"Melanoma Res"},{"key":"3491_CR105","doi-asserted-by":"publisher","first-page":"284","DOI":"10.54097\/hset.v6i.972","volume":"6","author":"D Jiang","year":"2022","unstructured":"Jiang D, Lyu Y, Miao R, Wang R. Toxicities of pembrolizumab in cancer patients. Highligh Sci Eng Technol. 2022;6:284\u201391.","journal-title":"Highligh Sci Eng Technol"},{"key":"3491_CR106","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.27112","author":"F Dalal","year":"2022","unstructured":"Dalal F, Dalal H, Baltz B. Pembrolizumab-induced myocarditis and delayed acute inflammatory demyelinating polyradiculoneuropathy. Cureus. 2022. https:\/\/doi.org\/10.7759\/cureus.27112.","journal-title":"Cureus"},{"issue":"1","key":"3491_CR107","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1159\/000497155","volume":"12","author":"C Zhou","year":"2019","unstructured":"Zhou C, Klionsky Y, Treasure M, Bruno D. Pembrolizumab-induced immune-mediated colitis in a patient with concurrent clostridium difficile infection. Case Rep Oncol. 2019;12(1):164\u201370. https:\/\/doi.org\/10.1159\/000497155.","journal-title":"Case Rep Oncol"},{"key":"3491_CR108","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.21708","author":"A Alias","year":"2022","unstructured":"Alias A, Hall J, Kulkarni P, Gowan A. Pembrolizumab-induced immune-mediated glossitis. Cureus. 2022. https:\/\/doi.org\/10.7759\/cureus.21708.","journal-title":"Cureus"},{"issue":"1","key":"3491_CR109","doi-asserted-by":"publisher","first-page":"e738","DOI":"10.1097\/cad.0000000000001162","volume":"33","author":"W Kian","year":"2021","unstructured":"Kian W, Zemel M, Elobra F, Sharb A, Levitas D, Assabag Y, et al. Intravenous immunoglobulin efficacy on pembrolizumab induced severe toxic epidermal necrolysis. Anticancer Drugs. 2021;33(1):e738\u201340. https:\/\/doi.org\/10.1097\/cad.0000000000001162.","journal-title":"Anticancer Drugs"},{"issue":"1","key":"3491_CR110","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1001\/jamadermatol.2015.2707","volume":"152","author":"C Hua","year":"2016","unstructured":"Hua C, Boussemart L, Mateus C, Routier \u00c9, Boutros C, Cazenave H, et al. Association of vitiligo with tumor response in patients with metastatic melanoma treated with pembrolizumab. JAMA Dermatol. 2016;152(1):45. https:\/\/doi.org\/10.1001\/jamadermatol.2015.2707.","journal-title":"JAMA Dermatol"},{"key":"3491_CR111","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000009431","author":"Z Wu","year":"2017","unstructured":"Wu Z, Lai L, Li M, Zhang L, Zhang W. Acute liver failure caused by pembrolizumab in a patient with pulmonary metastatic liver cancer. Medicine. 2017. https:\/\/doi.org\/10.1097\/md.0000000000009431.","journal-title":"Medicine"},{"issue":"3","key":"3491_CR112","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1158\/2326-6066.cir-17-0063","volume":"6","author":"A Lisberg","year":"2018","unstructured":"Lisberg A, Tucker D, Goldman J, Wolf B, Carroll J, Hardy A, et al. Treatment-related adverse events predict improved clinical outcome in NSCLC patients on keynote-001 at a single center. Cancer Immunol Res. 2018;6(3):288\u201394. https:\/\/doi.org\/10.1158\/2326-6066.cir-17-0063.","journal-title":"Cancer Immunol Res"},{"issue":"4","key":"3491_CR113","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1111\/ajco.12698","volume":"13","author":"K Roberts","year":"2017","unstructured":"Roberts K, Culleton V, Lwin Z, O\u2019Byrne K, Hughes B. Immune checkpoint inhibitors: navigating a new paradigm of treatment toxicities. Asia Pac J Clin Oncol. 2017;13(4):277\u201388. https:\/\/doi.org\/10.1111\/ajco.12698.","journal-title":"Asia Pac J Clin Oncol"},{"issue":"21","key":"3491_CR114","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.1200\/jco.21.00174","volume":"39","author":"M Reck","year":"2021","unstructured":"Reck M, Rodr\u00edguez-Abreu D, Robinson A, Hui R, Cs\u0151szi T, F\u00fcl\u00f6p A, et al. Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non\u2013small-cell lung cancer with pd-l1 tumor proportion score \u2265 50%. J Clin Oncol. 2021;39(21):2339\u201349. https:\/\/doi.org\/10.1200\/jco.21.00174.","journal-title":"J Clin Oncol"},{"key":"3491_CR115","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.35871","author":"H Ahdi","year":"2023","unstructured":"Ahdi H, AbdulMujeeb S, Nabrinsky E. Multiple autoimmune complications after a single dose of pembrolizumab. Cureus. 2023. https:\/\/doi.org\/10.7759\/cureus.35871.","journal-title":"Cureus"},{"issue":"28","key":"3491_CR116","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1200\/JCO.19.00934","volume":"37","author":"E Garon","year":"2019","unstructured":"Garon E, Hellmann M, Rizvi N, Carcereny E, Leighl N, Ahn M, et al. Five-year overall survival for patients with advanced non-small-cell lung cancer treated with pembrolizumab: results from the phase i keynote-001 study. J Clin Oncol. 2019;37(28):2518\u201327.","journal-title":"J Clin Oncol"},{"key":"3491_CR117","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2022.790225","author":"M Zhan","year":"2022","unstructured":"Zhan M, Xu T, Zheng H, He Z. Cost-effectiveness analysis of pembrolizumab in patients with advanced esophageal cancer based on the keynote-181 study. Front Public Health. 2022. https:\/\/doi.org\/10.3389\/fpubh.2022.790225.","journal-title":"Front Public Health"},{"key":"3491_CR118","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0663-4","author":"M Vugt","year":"2019","unstructured":"Vugt M, Greef SJ, Snyder E, Lipka L, Turner D, et al. Immunogenicity of pembrolizumab in patients with advanced tumors. J ImmunoTherapy Cancer. 2019. https:\/\/doi.org\/10.1186\/s40425-019-0663-4.","journal-title":"J ImmunoTherapy Cancer"},{"key":"3491_CR119","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.lungcan.2018.11.008","volume":"127","author":"C Choua\u00efd","year":"2019","unstructured":"Choua\u00efd C, Bensimon L, Clay E, Millier A, L\u00e9vy-Bachelot L, Huang M, et al. Cost-effectiveness analysis of pembrolizumab versus standard-of-care chemotherapy for first-line treatment of pd-l1 positive (>50%) metastatic squamous and non-squamous non-small cell lung cancer in france. Lung Cancer. 2019;127:44\u201352. https:\/\/doi.org\/10.1016\/j.lungcan.2018.11.008.","journal-title":"Lung Cancer"},{"issue":"3","key":"3491_CR120","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s41669-020-00255-2","volume":"5","author":"N Qiao","year":"2021","unstructured":"Qiao N, Insinga R, Lopes G, Cook J, S\u00e9n\u00e9cal M. A review of cost-effectiveness studies of pembrolizumab regimens for the treatment of advanced non-small cell lung cancer. PharmacoEconomics Open. 2021;5(3):365\u201383. https:\/\/doi.org\/10.1007\/s41669-020-00255-2.","journal-title":"PharmacoEconomics Open"},{"key":"3491_CR121","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.881787","author":"M Wu","year":"2022","unstructured":"Wu M, Qin S, Wang L, Tan C, Ye P, Zeng X, et al. Cost-effectiveness of pembrolizumab plus chemotherapy as first-line therapy for advanced oesophageal cancer. Front Pharmacol. 2022. https:\/\/doi.org\/10.3389\/fphar.2022.881787.","journal-title":"Front Pharmacol"},{"key":"3491_CR122","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-017-1986-9","author":"K Roseboom","year":"2017","unstructured":"Roseboom K, Dongen J, Tompa E, Tulder M, Bosmans J. Economic evaluations of health technologies in dutch healthcare decision-making: a qualitative study of the current and potential use, barriers, and facilitators. BMC Health Serv Res. 2017. https:\/\/doi.org\/10.1186\/s12913-017-1986-9.","journal-title":"BMC Health Serv Res"},{"key":"3491_CR123","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.562315","author":"S Chen","year":"2021","unstructured":"Chen S, Zhang Z, Zheng X, Tao H, Zhang S, Ma J, et al. Response efficacy of pd-1 and pd-l1 inhibitors in clinical trials: a systematic review and meta-analysis. Front Oncol. 2021. https:\/\/doi.org\/10.3389\/fonc.2021.562315.","journal-title":"Front Oncol"},{"key":"3491_CR124","first-page":"5","volume":"20","author":"V Pak","year":"2022","unstructured":"Pak V. The perfect combination of the most powerful cancer immunotherapy with the best targeted chemotherapy. Cancer Therapy Amp Oncol Internat J. 2022;20:5.","journal-title":"Cancer Therapy Amp Oncol Internat J"},{"issue":"62","key":"3491_CR125","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.ctrv.2017.10.002","volume":"1","author":"S Peters","year":"2018","unstructured":"Peters S, Kerr KM, Stahel R. PD-1 blockade in advanced NSCLC: A focus on pembrolizumab. Cancer Treat Rev. 2018;1(62):39\u201349.","journal-title":"Cancer Treat Rev"},{"key":"3491_CR126","doi-asserted-by":"publisher","first-page":"84","DOI":"10.54097\/hset.v8i.1114","volume":"8","author":"T Han","year":"2022","unstructured":"Han T, Li Y, Wang X. Pd-1\/pd-l1 blockade in cancer immunotherapy: clinical benefits, limitations and beyond. Highligh Sci Eng Technol. 2022;8:84\u201393.","journal-title":"Highligh Sci Eng Technol"},{"key":"3491_CR127","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.733890","author":"K Hradsk\u00e1","year":"2021","unstructured":"Hradsk\u00e1 K, Jelinek T. Toxicity of immune-checkpoint inhibitors in hematological malignancies. Front Pharmacol. 2021. https:\/\/doi.org\/10.3389\/fphar.2021.733890.","journal-title":"Front Pharmacol"},{"key":"3491_CR128","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k4226","author":"C Xu","year":"2018","unstructured":"Xu C, Chen Y, Du X, Liu J, Huang C, Chen L, et al. Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis. BMJ. 2018. https:\/\/doi.org\/10.1136\/bmj.k4226.","journal-title":"BMJ"},{"key":"3491_CR129","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2022\/2647825","volume":"2022","author":"S Chen","year":"2022","unstructured":"Chen S, Li Y, Zhu Y, Fei J, Song L, Sun G, et al. Serpine1 overexpression promotes malignant progression and poor prognosis of gastric cancer. J Oncol. 2022;2022:1\u201317. https:\/\/doi.org\/10.1155\/2022\/2647825.","journal-title":"J Oncol"},{"issue":"17","key":"3491_CR130","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.1182\/blood-2016-12-756841","volume":"129","author":"Y Kwong","year":"2017","unstructured":"Kwong Y, Chan T, Tan D, Kim S, Poon L, Mow B, et al. Pd1 blockade with pembrolizumab is highly effective in relapsed or refractory nk\/t-cell lymphoma failing l-asparaginase. Blood. 2017;129(17):2437\u201342. https:\/\/doi.org\/10.1182\/blood-2016-12-756841.","journal-title":"Blood"},{"issue":"1","key":"3491_CR131","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1080\/21655979.2021.2018096","volume":"13","author":"L Liu","year":"2022","unstructured":"Liu L, Xiao S, Wang Y, Zhu Z, Cao Y, Yang S, et al. Identification of a novel circular rna circznf652\/mir-486-5p\/serpine1 signaling cascade that regulates cancer aggressiveness in glioblastoma (gbm). Bioengineered. 2022;13(1):1411\u201323. https:\/\/doi.org\/10.1080\/21655979.2021.2018096.","journal-title":"Bioengineered"},{"key":"3491_CR132","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1200\/edbk_280503","volume":"40","author":"A Green","year":"2020","unstructured":"Green A, Feinberg J, Makker V. A review of immune checkpoint blockade therapy in endometrial cancer. Am Soc Clin Oncol Educ Book. 2020;40:238\u201344. https:\/\/doi.org\/10.1200\/edbk_280503.","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"12","key":"3491_CR133","doi-asserted-by":"publisher","first-page":"3063","DOI":"10.3390\/cancers13123063","volume":"13","author":"V Randrian","year":"2021","unstructured":"Randrian V, Evrard C, Tougeron D. Microsatellite instability in colorectal cancers: carcinogenesis, neo-antigens, immuno-resistance and emerging therapies. Cancers. 2021;13(12):3063. https:\/\/doi.org\/10.3390\/cancers13123063.","journal-title":"Cancers"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-024-03491-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-024-03491-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-024-03491-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T04:08:34Z","timestamp":1726718914000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-024-03491-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,24]]},"references-count":133,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2024,10]]}},"alternative-id":["3491"],"URL":"https:\/\/doi.org\/10.1007\/s12094-024-03491-8","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,24]]},"assertion":[{"value":"1 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that have no competing interests or other interests that might be perceived to influence the results and\/or discussion reported in this paper.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}